Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
出版年份 2021 全文链接
标题
Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
作者
关键词
DILI, drug-induced liver injury, hepatotoxicity, liver enzymes, steroids
出版物
JOURNAL OF HEPATOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-09-03
DOI
10.1016/j.jhep.2021.08.024
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase
- (2020) Olivier Vollmer et al. AUTOIMMUNITY REVIEWS
- HLA associations with infliximab-induced liver injury
- (2020) Christopher D. Bruno et al. PHARMACOGENOMICS JOURNAL
- Drug-Induced Liver Injury — Types and Phenotypes
- (2019) Jay H. Hoofnagle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute Liver Failure from Tumor Necrosis Factor-α Antagonists: Report of Four Cases and Literature Review
- (2018) Beverley Kok et al. DIGESTIVE DISEASES AND SCIENCES
- Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications
- (2018) Kalaiyarasi Kaliyaperumal et al. JOURNAL OF HEPATOLOGY
- Low prevalence of hepatitis E in Iceland: a seroepidemiological study
- (2018) Arthur Löve et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study
- (2017) Paola Nicoletti et al. GASTROENTEROLOGY
- Graphtyper enables population-scale genotyping using pangenome graphs
- (2017) Hannes P Eggertsson et al. NATURE GENETICS
- Reply
- (2016) Ynto S. De Boer et al. Clinical Gastroenterology and Hepatology
- Risk of Drug-Induced Liver Injury From Tumor Necrosis Factor Antagonists
- (2015) Einar S. Björnsson et al. Clinical Gastroenterology and Hepatology
- Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports
- (2015) Einar S. Björnsson et al. HEPATOLOGY
- Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases
- (2015) Susana Rodrigues WORLD JOURNAL OF GASTROENTEROLOGY
- Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO
- (2014) B. Glintborg et al. RHEUMATOLOGY
- Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases
- (2013) Marwan Ghabril et al. Clinical Gastroenterology and Hepatology
- Infliximab-Related Hepatitis: A Case Study and Literature Review
- (2013) Francisco Colina et al. DIGESTIVE DISEASES AND SCIENCES
- Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland
- (2013) Einar S. Björnsson et al. GASTROENTEROLOGY
- Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission
- (2012) Nicole M.F. van Gerven et al. JOURNAL OF HEPATOLOGY
- Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
- (2011) G P Aithal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury
- (2011) Ayako Suzuki et al. HEPATOLOGY
- Patients With Typical Laboratory Features of Autoimmune Hepatitis Rarely Need a Liver Biopsy for Diagnosis
- (2010) Einar Björnsson et al. Clinical Gastroenterology and Hepatology
- Simplified criteria for the diagnosis of autoimmune hepatitis
- (2008) Elke M. Hennes et al. HEPATOLOGY
- Detection of sharing by descent, long-range phasing and haplotype imputation
- (2008) Augustine Kong et al. NATURE GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started